SynthesisBMC infectious diseases2026
Host genetic factors modulating dengue virus: a systematic review of TLR polymorphisms.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDengue virus (DENV) infection is a substantial global public health burden, affecting ~ 390 million people every year, with a mortality rate of ~ 2.5% of those requiring hospitalization. Despite implementing vaccination and outbreak controls, DENV infection incidence continues to rise, particularly in endemic tropical and subtropical regions. Toll-like receptors (TLRs), as key components of the innate immune system, play a crucial role in recognizing DENV and initiating immune responses. Genetic variations, such as single-nucleotide polymorphisms (SNPs), in TLR genes may alter their function and expression levels, which in turn affect an individual's susceptibility to dengue and the severity of the disease. Defining these associations is critical for dengue risk stratification, prognosis, treatment strategies, and vaccine development. Currently, no review has comprehensively defined these associations; therefore, this study aimed to systematically evaluate TLR gene variants and their association with DENV infection susceptibility and severity.
methodsA systematic search was performed across major databases, including PubMed/MEDLINE, EMBASE, Scopus, and Web of Science, covering reports published up to April 20, 2025. Prospective or retrospective observational studies (case-control and cohort) investigating the association between TLR SNPs and dengue susceptibility and severity were included. Descriptive data were independently extracted by two reviewers using a standardized workflow, and bias risk was assessed using an adapted Newcastle-Ottawa Scale for case-control studies.
resultsEight case-control studies from India, Mexico, Colombia, and Indonesia met the inclusion criteria from an initial 65 records. All the included studies were assessed as having acceptable quality. Although studies demonstrate heterogeneity in their methods, TLR3 rs3775291 and rs3775290, TLR4 rs4986790 and rs4986791, and TLR7 rs179008 and rs3853839 were among the most studied SNPs that exhibited correlation with dengue susceptibility and/or severity.
conclusionCertain SNPs in TLR3, TLR4, TLR7, TLR8, and TLR9 demonstrate associations with dengue susceptibility. All of these, except TLR4 and TLR9, demonstrated some correlation with severity and/or certain clinical outcomes. The heterogeneity and limitations of the reviewed studies, as indicated by finding discrepancies, highlight the complexity of these genetic associations. Therefore, further large-scale, multi-ethnic prospective studies with standardized methodologies and functional validation are required to clarify the role of TLR SNPs in dengue pathogenesis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.